HomeCompareLMLLF vs JNJ

LMLLF vs JNJ: Dividend Comparison 2026

LMLLF yields 26315.79% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LMLLF wins by $802085897127229390848.00M in total portfolio value
10 years
LMLLF
LMLLF
● Live price
26315.79%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$802085897127229390848.00M
Annual income
$796,134,651,160,688,600,000,000,000.00
Full LMLLF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — LMLLF vs JNJ

📍 LMLLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLMLLFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LMLLF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LMLLF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LMLLF
Annual income on $10K today (after 15% tax)
$2,236,842.11/yr
After 10yr DRIP, annual income (after tax)
$676,714,453,486,585,300,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, LMLLF beats the other by $676,714,453,486,585,300,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LMLLF + JNJ for your $10,000?

LMLLF: 50%JNJ: 50%
100% JNJ50/50100% LMLLF
Portfolio after 10yr
$401042948563614695424.00M
Annual income
$398,067,325,580,344,300,000,000,000.00/yr
Blended yield
99.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

LMLLF
No analyst data
Altman Z
-103.8
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LMLLF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLMLLFJNJ
Forward yield26315.79%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$802085897127229390848.00M$30.3K
Annual income after 10y$796,134,651,160,688,600,000,000,000.00$4,689.40
Total dividends collected$801694023521105215488.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LMLLF vs JNJ ($10,000, DRIP)

YearLMLLF PortfolioLMLLF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,642,279$2,631,578.95$10,592$272.30+$2.63MLMLLF
2$652,674,496$649,847,257.10$11,289$357.73+$652.66MLMLLF
3$150,717,093,655$150,018,731,944.79$12,123$472.89+$150717.08MLMLLF
4$32,537,594,543,311$32,376,327,253,099.92$13,141$629.86+$32537594.53MLMLLF
5$6,567,124,460,012,792$6,532,309,233,851,450.00$14,408$846.81+$6567124460.00MLMLLF
6$1,239,202,870,261,231,900$1,232,176,047,089,018,000.00$16,021$1,151.60+$1239202870261.22MLMLLF
7$218,624,156,631,620,120,000$217,298,209,560,440,600,000.00$18,122$1,588.22+$218624156631620.09MLMLLF
8$36,062,384,982,353,154,000,000$35,828,457,134,757,322,000,000.00$20,930$2,228.20+$36062384982353152.00MLMLLF
9$5,561,912,118,262,444,000,000,000$5,523,325,366,331,326,000,000,000.00$24,792$3,191.91+$5561912118262444032.00MLMLLF
10$802,085,897,127,229,400,000,000,000$796,134,651,160,688,600,000,000,000.00$30,274$4,689.40+$802085897127229390848.00MLMLLF

LMLLF vs JNJ: Complete Analysis 2026

LMLLFStock

Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.

Full LMLLF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this LMLLF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LMLLF vs SCHDLMLLF vs JEPILMLLF vs OLMLLF vs KOLMLLF vs MAINLMLLF vs ABBVLMLLF vs MRKLMLLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.